Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06534723
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-03
Brief Title:
Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimers Dementia Syndrome of Deficiency of Spleen and Kidney
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A 12-month Multicenter Randomized Double-blind Placebo-controlled Parallel Group Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimers Dementia Syndrome of Deficiency of Spleen and Kidney
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a randomized double-blind placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimers dementia
Detailed Description:
This is a multi-center randomized double-blind placebo-controlled phase 3 clinical trial targeting patients with mild-to-moderate Alzheimers dementia TCM differentiated as syndrome of deficiency of spleen and kidney 570 subjects were recruited and randomly assigned to the experimental and placebo groups at a ratio of 21
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None